Page last updated: 2024-10-23

bohemine and Neoplasms

bohemine has been researched along with Neoplasms in 2 studies

bohemine : Purine substituted on C-2, C-6 and N-9 with (3-hydroxypropyl)amino, benzylamino and isopropyl groups respectively; a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor that is structurally similar to olomoucine and roscovitine.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Determination of pharmacokinetic properties in the intact animal remains a major bottleneck in drug discovery."1.32Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis. ( Fischer, PM; Goddard, PM; Lane, DP; Nutley, BP; Raynaud, FI; Workman, P, 2004)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Raynaud, FI1
Fischer, PM1
Nutley, BP1
Goddard, PM1
Lane, DP1
Workman, P1
Skalnikova, H1
Halada, P1
Dzubak, P1
Hajduch, M1
Kovarova, H1

Other Studies

2 other studies available for bohemine and Neoplasms

ArticleYear
Cassette dosing pharmacokinetics of a library of 2,6,9-trisubstituted purine cyclin-dependent kinase 2 inhibitors prepared by parallel synthesis.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:3

    Topics: Animals; Area Under Curve; CDC2-CDC28 Kinases; Cyclin-Dependent Kinase 2; Dose-Response Relationship

2004
Protein fingerprints of anti-cancer effects of cyclin-dependent kinase inhibition: identification of candidate biomarkers using 2-D liquid phase separation coupled to mass spectrometry.
    Technology in cancer research & treatment, 2005, Volume: 4, Issue:4

    Topics: Animals; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor;

2005